Service Quote Request
Please fill out the form below with your detailed inquiry.
-
PHONE: 1-866-918-6812
VECTOR Technologies
SignaGen develops cutting-edge technologies for the production of chemical transfection reagents and high-quality viral vectors
RANPS™ Approach to Enhance AAV Yield
Swap the original weak promoter with a strong native rAAV promoter to substantially enhance AAV production yield…
LentiMAX™ Lentivirus Packaging System
A 3rd gen lentiviral packaging system incorporating a inhibitory miRNA module to reliably achieve titers exceeding 10⁹ TU/mL
Ad.MAX™ Adenovirus Packaging System
Transgene expression is markedly suppressed during adenoviral packaging, enabling the production of high-titer virus even when expressing cytotoxic transgenes…
Biodegradable Polymer Synthesis
The cationic polymer is engineered to undergo degradation following endocytosis of the polymer–DNA complex, resulting in markedly reduced cytotoxicity to host cells while maintaining exceptionally high transfection efficiency…
Polymer with PDCC™ Technologies
The cationic polymer is engineered to undergo pH-dependent conformational changes, providing exceptional capability for transfecting short single- or double-stranded RNAs…
RANPS™ Approach to Enhance AAV Yield
In conventional AAV production systems, expression of the large Rep proteins (Rep78/68) is driven by the native P5 promoter, which exhibits only ~5% of the transcriptional activity of the downstream P40/P41 promoters. This relatively weak transcriptional activity often limits Rep availability and can become a bottleneck for efficient AAV genome replication during vector production.
To address this limitation, we developed the Recombinant AAV Native Promoter Swap (RANPS™) strategy. In this system, the native P5 promoter is replaced with a truncated P41 promoter derived from AAV5, which is transiently activated during the production phase to enhance Rep78/68 expression. Importantly, this controlled increase in Rep expression is sufficient to stimulate efficient AAV genome replication while remaining below levels that would otherwise induce significant cytotoxicity or compromise producer cell viability.
The resulting elevation of Rep78/68 levels accelerates AAV genome replication, improves capsid assembly kinetics, and enhances genome packaging efficiency. Collectively, the RANPS™ platform can increase rAAV production yields by up to tenfold compared with conventional P5-driven systems, providing a robust and scalable strategy for high-titer rAAV manufacturing.
LentiMAX™ Lentivirus Packaging System
The LentiMAX system is a third-generation, high-yield platform for the production of recombinant lentiviral vectors that addresses a key cellular bottleneck during viral packaging: activation of the host Integrated Stress Response (ISR). During conventional lentivirus production, high levels of viral protein expression can activate the antiviral kinase PKR, which subsequently phosphorylates eIF2α, triggering a global shutdown of protein translation. This translational arrest significantly limits the synthesis of viral structural and regulatory proteins and ultimately reduces lentiviral yield.
The LentiMAX system overcomes this limitation through a proprietary packaging formulation that incorporates miRNA-based components designed to suppress activation of the PKR–eIF2α signaling pathway. By attenuating this ISR-mediated translational inhibition, the system enables producer cells—typically LentiMAX Packaging Cells—to maintain sustained, high-level synthesis of the viral proteins required for vector assembly. As a result, viral genome packaging, particle assembly, and release proceed more efficiently, leading to substantially higher infectious lentiviral titers compared with conventional lentivirus production methods.
Ad.MAX™ Adenovirus Packaging System
Ad.MAX™ technology was developed to maximize adenovirus production through genetic modification of both the packaging cell line and the adenoviral vector system. This platform utilizes engineered HEK293 packaging cells together with modified adenoviral shuttle vectors or adenoviral genomes to optimize viral yield.
The core of this proprietary technology lies in a genetically engineered HEK293 cell line in which adenoviral replication remains fully functional while viral protein expression during the packaging process is selectively suppressed. This design allows the virus to replicate efficiently without producing high levels of viral or transgene proteins that may otherwise compromise cell viability.
In conjunction with this modified packaging cell line, the adenoviral genome contains a trans-acting regulatory element that specifically interacts with the suppressor cassette engineered in the HEK293 cells. This coordinated system enables high-efficiency adenovirus replication with minimal protein expression during viral packaging, thereby preserving cell health and significantly improving viral yield.
The Ad.MAX™ system is particularly advantageous for packaging adenoviral vectors carrying toxic genes of interest (GOIs). In conventional systems, expression of toxic transgenes during viral production can rapidly kill HEK293 cells, leading to severe reductions in adenovirus yield. By suppressing transgene expression during packaging while maintaining viral replication, Ad.MAX™ enables efficient production of such vectors.
Overall, Ad.MAX™ technology allows researchers to package a wide range of genes—up to approximately 7.5 kb in size—into adenoviral vectors with improved efficiency and reliability, even when the transgene exhibits cellular toxicity.
Biodegradable Polymer Synthesis
This BDP technology is our patent-pending proprietary platform that enables the synthesis of a biodegradable polycationic polymer for gene delivery applications.
Unlike conventional cationic polymers—such as poly(L-lysine) and poly(ethylenimine)—or cationic liposomes, this novel polymer features a unique biodegradable backbone that undergoes controlled degradation after the gene vector releases its DNA or RNA cargo inside mammalian cells (Figure 1). This degradable structure significantly reduces intracellular polymer accumulation, resulting in substantially lower cytotoxicity compared with traditional non-degradable transfection reagents.
In addition, the polymer is engineered to exhibit strong nucleic acid binding affinity and high buffering capacity, two critical characteristics required for efficient gene delivery systems. These properties facilitate stable nucleic acid complex formation and promote effective endosomal escape following cellular uptake.
In in vitro DNA transfection experiments, this biodegradable polymer demonstrated 2~. 10× higher transfection efficiency than poly(ethylenimine) when delivering plasmid DNA into HEK293T cells, highlighting its potential as a highly effective and low-toxicity gene delivery carrier.
Polymer with PDCC™ Technologies for Best siRNA Transfection
Liposome- and polymer-based reagents often provide very efficient DNA delivery, but they frequently perform poorly when used for siRNA transfection in mammalian cells. This reduced efficiency is largely attributed to the short length of the siRNA anionic backbone, which provides insufficient electrostatic interaction with cationic lipids or polycationic polymers. As a result, siRNA lipoplexes or polyplexes are less stable and can readily dissociate when they encounter the highly polyanionic surface of mammalian cells, leading to inefficient intracellular delivery.
To address this limitation, we engineered liposome and polymer formulations by incorporating specific hydrophobic modifications that introduce pH-Dependent Conformational Changes (PDCC) under physiological conditions. These hydrophobic groups enhance intermolecular interactions and significantly stabilize siRNA lipoplex or polyplex nanoparticles, preventing premature dissociation during cellular interaction.
An additional advantage of the PDCC technology is the ability to precisely control nanoparticle size. By tuning the hydrophobic modifications, siRNA complexes can be assembled into virus-like nanoparticles, which are optimal for cellular uptake. Together, these features greatly enhance the stability, cellular entry, and overall transfection efficiency of siRNA delivery systems.
Get in Touch With Us
For scientific inquiries, technical assistance, or potential collaborations, our team is readily available — please do not hesitate to contact us
Important updates waiting for you!
Enter your email address below and subscribe to our newsletter